Skip to main content
Springer Nature Link
Log in

Survival advantage of lymphadenectomy in endometrial cancer

  • Original Article – Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The lymphadenectomy in the treatment of endometrial cancer is a topic of ongoing debate. The direct comparison between no lymphadenectomy, pelvic lymphadenectomy, and pelvic/para-aortic lymphadenectomy regarding overall survival of patients with endometrial cancer is missing.

Methods

We performed a multicenter, retrospective, registry-based study of 1502 patients with endometrial cancer treated with no lymphadenectomy (n = 697), systemic pelvic lymphadenectomy (n = 543) and systemic pelvic/para-aortic lymphadenectomy (n = 262). The patients were divided into three groups of recurrence risk: low, intermediate, and high. The outcome measure was overall survival.

Results

Median follow-up was 78 months. Lymphadenectomy did not improve overall survival of patients with low risk of recurrence. The survival effect of systemic lymphadenectomy was significant in patients with intermediate and high risk of recurrence. Multivariate analysis showed that both pelvic (HR 0.63, CI 0.38–0.82, p = 0.001) and combination of pelvic/para-aortic lymphadenectomy (HR 0.50, CI 0.43–0.81, p < 0.0001) significantly reduced the mortality risk in patients with intermediate risk compared to the patients who underwent no lymphadenectomy. In patients with high risk, only combined pelvic/para-aortic lymphadenectomy (HR 0.62, CI 0.48–0.82, p = 0.005) was associated with decreased mortality rate compared with no lymphadenectomy. Among patients with intermediate and high risk of recurrence who did not receive any adjuvant therapy, pelvic/para-aortic lymphadenectomy significantly reduced the mortality risk (HR 0.52, CI 0.37–0.73, p < 0.0001) in comparison with no lymphadenectomy. This management was superior to pelvic lymphadenectomy alone. In patients with low risk of recurrence, lymphadenectomy had no effect on overall survival.

Conclusions

Pelvic/para-aortic lymphadenectomy should be performed in all patients with endometrial cancer at intermediate and high risk of recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  • Bassarak N, Blankenstein T, Bruning A, Dian D, Bergauer F, Friese K, Mylonas I (2010) Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium? BMC Cancer 10:224

    Article  PubMed  PubMed Central  Google Scholar 

  • Battista MJ, Steiner E, Rieks N, Steetskamp J, Seeger A, Sicking I, Bohm D, Schmidt M, Koelbl H (2013) Nationwide analysis on surgical staging procedures and systemic treatment for patients with endometrial cancer in Germany. Int J Gynecol Cancer 23:105–112

    Article  PubMed  Google Scholar 

  • Bogani G, Dowdy SC, Cliby WA, Ghezzi F, Rossetti D, Mariani A (2014) Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence. J Obstet Gynaecol Res 40:301–311

    Article  PubMed  PubMed Central  Google Scholar 

  • Burke TW, Levenback C, Tornos C, Morris M, Wharton JT, Gershenson DM (1996) Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study. Gynecol Oncol 62:169–173

    Article  CAS  PubMed  Google Scholar 

  • Chan JK, Kapp DS (2007) Role of complete lymphadenectomy in endometrioid uterine cancer. Lancet Oncol 8(9):831–841

    Article  PubMed  Google Scholar 

  • Chan JK, Cheung MK, Huh WK, Osann K, Husain A, Teng NN, Kapp DS (2006) Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 107:1823–1830

    Article  PubMed  Google Scholar 

  • Chan JK, Urban R, Cheung MK, Shin JY, Husain A, Teng NN, Berek JS, Walker JL, Kapp DS, Osann K (2007) Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients. Cancer 109:2454–2460

    Article  PubMed  Google Scholar 

  • Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, Sessa C (2011) Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):VI35–VI39

    PubMed  Google Scholar 

  • Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A (2005) Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 23:3668–3675

    Article  PubMed  Google Scholar 

  • Fotopoulou C, Savvatis K, Kraetschell R, Schefold JC, Lichtenegger W, Sehouli J (2010) Systematic pelvic and aortic lymphadenectomy in intermediate and high-risk endometrial cancer: lymph-node mapping and identification of predictive factors for lymph-node status. Eur J Obstet Gynecol Reprod Biol 149:199–203

    Article  PubMed  Google Scholar 

  • Huang CY, Ho CM, Chen YL, You SL, Chen CA, Cheng WF (2013) Impact of lymphadenectomy in uterine endometrioid carcinoma. Eur J Surg Oncol 39:350–357

    Article  PubMed  Google Scholar 

  • Ignatov T, Eggemann H, Burger E, Fettke F, Costa SD, Ignatov A (2015) Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade. Breast Cancer Res Treat 151:357–364

    Article  CAS  PubMed  Google Scholar 

  • Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373:125–136

    Article  CAS  PubMed  Google Scholar 

  • Maggino T, Romagnolo C, Zola P, Sartori E, Landoni F, Gadducci A (1995) An analysis of approaches to the treatment of endometrial cancer in western Europe: a CTF study. Eur J Cancer 31:1993–1997

    Article  Google Scholar 

  • Mariani A, Dowdy SC, Cliby WA, Haddock MG, Keeney GL, Lesnick TG, Podratz KC (2006) Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients. Gynecol Oncol 101:200–208

    Article  PubMed  Google Scholar 

  • Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO, Podratz KC (2008) Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 109:11–18

    Article  PubMed  PubMed Central  Google Scholar 

  • May T, Shoni M, Vitonis AF, Quick CM, Growdon WB, Muto MG (2013) The role of para-aortic lymphadenectomy in the surgical staging of women with intermediate and high-risk endometrial adenocarcinomas. Int J Surg Oncol 2013:858916

    PubMed  PubMed Central  Google Scholar 

  • Panici PB, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, Angioli R, Tateo S, Mangili G, Katsaros D, Garozzo G, Campagnutta E, Donadello N, Greggi S, Melpignano M, Raspagliesi F, Ragni N, Cormio G, Grassi R, Franchi M, Giannarelli D, Fossati R, Torri V, Amoroso M, Croce C, Mangioni C (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716

    Article  Google Scholar 

  • Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104

    Article  PubMed  Google Scholar 

  • Shepherd JH (1989) Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 96:889–892

    Article  CAS  PubMed  Google Scholar 

  • Smith DC, Macdonald OK, Lee CM, Gaffney DK (2008) Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis. Int J Gynecol Cancer 18:255–261

    Article  CAS  PubMed  Google Scholar 

  • Soliman PT, Frumovitz M, Spannuth W, Greer MJ, Sharma S, Schmeler KM, Ramirez PT, Levenback CF, Ramondetta LM (2010) Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists. Gynecol Oncol 119:291–294

    Article  PubMed  PubMed Central  Google Scholar 

  • Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N (2010) Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 375:1165–1172

    Article  PubMed  Google Scholar 

  • Toptas T, Simsek T (2015) Survival analysis of pelvic lymphadenectomy alone versus combined pelvic and para-aortic lymphadenectomy in patients exhibiting endometrioid type endometrial cancer. Oncol Lett 9:355–364

    PubMed  PubMed Central  Google Scholar 

  • von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370:1453–1457

    Article  Google Scholar 

  • Wang ZQ, Wang JL, Shen DH, Li XP, Wei LH (2013) Should all endometrioid uterine cancer patients undergo systemic lymphadenectomy? Eur J Surg Oncol 39:344–349

    Article  PubMed  Google Scholar 

  • Watanabe Y, Aoki D, Kitagawa R, Takeuchi S, Sagae S, Sakuragi N, Yaegashi N (2007) Status of surgical treatment procedures for endometrial cancer in Japan: results of a Japanese Gynecologic Oncology Group survey. Gynecol Oncol 105:325–328

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Department of Obstetrics and Gynecology, Otto-von-Guericke University, G.-Hauptmann Str. 35, 39108, Magdeburg, Germany

      Holm Eggemann, Tanja Ignatov, Katharina Kaiser, Serban Dan Costa & Atanas Ignatov

    2. Institute of Biometry and Medical Informatics, Otto-von-Guericke University, Magdeburg, Germany

      Elke Burger

    Authors
    1. Holm Eggemann
      View author publications

      You can also search for this author inPubMed Google Scholar

    2. Tanja Ignatov
      View author publications

      You can also search for this author inPubMed Google Scholar

    3. Katharina Kaiser
      View author publications

      You can also search for this author inPubMed Google Scholar

    4. Elke Burger
      View author publications

      You can also search for this author inPubMed Google Scholar

    5. Serban Dan Costa
      View author publications

      You can also search for this author inPubMed Google Scholar

    6. Atanas Ignatov
      View author publications

      You can also search for this author inPubMed Google Scholar

    Corresponding author

    Correspondence to Atanas Ignatov.

    Ethics declarations

    Conflict of interest

    All authors declare that they have no conflict of interest.

    Animal and human rights statement

    This article does not contain any studies with animals performed by any of the authors.

    Ethical standard

    All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

    Informed consent

    Written informed consent was obtained from all patients before treatment. An additional individual consent for this analysis was not needed.

    Additional information

    Holm Eggemann and Tanja Ignatov have contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Eggemann, H., Ignatov, T., Kaiser, K. et al. Survival advantage of lymphadenectomy in endometrial cancer. J Cancer Res Clin Oncol 142, 1051–1060 (2016). https://doi.org/10.1007/s00432-015-2109-9

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00432-015-2109-9

    Keywords